Crocker and colleagues’ data suggest that, in glioblastoma patients, a higher serum TIMP1 level at tumor presentation predicted shorter survival and that TIMP1 levels in the glioblastoma patients are significantly higher than in normal controls [6]. This evidence concerns the gene TIMP1 and glioblastoma.